Novakid Maintains Growth in 2022, Launches 40-Minute Learning Sessions
22.2.2023 18:00:00 EET | Business Wire | Press release
Novakid, a leading online English as a Second Language (ESL) platform and evolving EdTech company that is reinventing learning for children, maintained customer growth with approximately 70,000 new students across 50+ countries subscribing during 2022.
Importantly, Novakid achieved double-digit YoY revenue growth, with the share of long-term subscriptions (6 and 12 months) steadily increasing. Globally, over 20% of new subscription sales are attributed to referrals from current customers and NPS is trending at above 60% (best in class), evident in the improved customer retention figures. Novakid maintained high scores for customer satisfaction - an average of 96%, depending on the region - based on internal measurement methods conducted on a regular basis.
Over 10 million lessons have been delivered since 2017, of which nearly 4.5 million lessons (4,453,732) were completed in 2022.
Novakid continued to strengthen its positions in global markets. Europe still accounts for the majority of the company’s client portfolio (55%) with the MENA region accounting for 25% of the client base and the Asia-Pacific region increasing to 20% of the total number of customers.
2023 plans
The 25-minute one-on-one English lesson format will be upgraded to a 40-minute educational journey for young students. These extended sessions are at no additional cost to clients and include three elements: a fun, context-setting pre-lesson activity, the one-on-one lesson with a teacher and gamified self-practice ‘homework’ after the lesson. Since August 2022, Novakid has noted that the average time students spend on self-practice activities beyond structured, one-to-one lessons has tripled.
New product developments that are being considered for the platform are aimed at increasing the engagement with educational content to increase motivation to learn and support learning outcomes. The team is constantly researching and testing various options, including experiments with other subjects that could be added to the product line.
Recent research has indicated that increased time spent on homework and mini games has a positive impact on the retention rate. Additionally, the monthly retention rate of users who have watched comic-based videos is 149% higher than those who have not. Ultimately, more interaction with games, videos and additional content results in higher retention rates. This insight will drive curriculum and product development going forward.
“Our focus in the upcoming year will lie on further improving the value of our product for our customers. We will do this by continuing to invest in better UX for customers, and in high-quality content for our teachers helping them to be even better at teaching. We will continue expanding our offering beyond the one-to-one tutoring format. Specifically, we are planning to add self-learning activities and start introducing 1-many learning & practice products. We are grateful for the trust that our families put in us to teach their children. The results of our young English learners remain the biggest achievement for Novakid,” said Max Azarov, CEO of Novakid.
For more information about Novakid, please visit https://www.novakidschool.com/corp/.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230222005563/en/
Contact information
Dominique Harmse, +447932928310
dominique.harmse@novakidschool.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 20263.10.2026 17:50:00 EEST | Press release
Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced three-year follow-up results from the ovarian cancer cohort of its 400+ patient Phase 1b C-800-01 trial. The study evaluated botensilimab (BOT), Agenus’ multifunctional, Fc-enhanced anti-CTLA-4 antibody, in combination with balstilimab (BAL), Agenus’ anti-PD-1 antibody. The results, including three-year survival and outcomes by sensitivity to platinum-based chemotherapy and by prior treatment, were presented at the 2026 International Gynecologic Cancer Society (IGCS) Annual Global Meeting in Montréal, Canada. Among patients evaluable for efficacy, three-year overall survival was 48% (n=35), unchanged from the two-year estimate, suggesting durable clinical benefit in this population. Responses and long-term survival were observed in both platinum-sensitive and platinum-resistant or refractory disease. At the last follow-up, 25% of patients who received at least one dose of treatment (11 of 44) were alive
emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer2.10.2026 18:12:00 EEST | Press release
emnify, a global leader in IoT connectivity, today announced the appointments of Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer, effective immediately. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001902751/en/ emnify Appoints Sacha Herrmann as Chief Financial Officer and Christian Friis as Chief Revenue Officer The appointments follow the recent naming of Kenneth De Spiegeleire as Chief Executive Officer and Frank Stoecker as Executive Chairman of the Board. Together, these leadership changes strengthen emnify financial, operational, and commercial capabilities as the company enters its next phase of international growth. “We have proven momentum. Our ambition is to now turn it into global category leadership,” said Kenneth De Spiegeleire, CEO of emnify. “That requires sharper focus, disciplined execution, and the right capabilities in the right seats. Sacha brings financial lead
Tacton Appoints Former IFS Executive Merlin Knott as Chief Commercial Officer to Accelerate Global Growth and Scale Beyond CPQ2.10.2026 16:00:00 EEST | Press release
Tacton, a global leader in Configure, Price, Quote (CPQ) software and configuration solutions for manufacturers of complex products, today announced the appointment of Merlin Knott as Chief Commercial Officer (CCO). In this role, Knott will lead Tacton’s global commercial organization, including marketing, sales, and pre-sales, aligning the teams responsible for bringing Tacton’s solutions to market, and driving value to its customers and partners globally. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261002794882/en/ Merlin Knott, Chief Commercial Officer, Tacton Knott joins Tacton with decades of experience building and scaling commercial organizations across the enterprise software industry. Most recently, he held senior leadership roles at IFS, the world’s leading provider of Industrial AI software, where he led global partner and channel operations before becoming President of the company’s Enterprise Service Manageme
EDW Presents 2026 Data Quality Award to Repeat Winner Domivest2.10.2026 16:00:00 EEST | Press release
European DataWarehouse (EDW) presented its fifth annual Data Quality Award at the 2026 TSI Congress in Berlin. This year, EDW's Best Data Quality – Deal of the Year (2026) award was presented to Domivest B.V. for its transaction Domi 2023-1 B.V., recognising the firm's outstanding commitment to accurate, complete, and consistent reporting. The award is based on EDW's proprietary data quality scoring methodology, which evaluates transactions against thousands of validation rules and checks. Data quality excellence is not a one-off achievement. The fact that the same issuers continue to rank among the top performers year after year demonstrates that superior data quality is the result of sustained commitment, robust processes, and ongoing investment. "Receiving the Data Quality Award for a second time means a great deal to us. Transparent, accurate loan-level data is key to investor trust in our transactions, and we are grateful to European DataWarehouse for recognising the work our trea
ILiAD Biotechnologies Expands BPZE1 Public Health and Commercial Potential with Publication of Pediatric Phase 2b Study in The Lancet Infectious Diseases2.10.2026 15:00:00 EEST | Press release
ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robust nasal mucosal immune responses in healthy children aged 6 through 17 years (LINK). The study demonstrated that a single intranasal dose of BPZE1 induced nasal mucosal immune responses against all Bordetella pertussis antigens tested and was well tolerated, both when administered alone and when co-administered with a tetanus-diphtheria-acellular pertussis (Tdap) booster vaccine. The multi-center Phase 2b trial enrolled 366 participants across 16 sites in the United Kingdom, Australia, and Costa Rica and included participants
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
